Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Authors
Middleton, GPalmer, D
Greenhalf, W
Ghaneh, P
Jackson, R
Cox, T
Evans, A
Shaw, V
Wadsley, J
Valle, Juan W
Propper, D
Wasan, H
Falk, S
Cunningham, D
Coxon, F
Ross, P
Madhusudan, S
Wadd, N
Corrie, P
Hickish, T
Costello, E
Campbell, F
Rawcliffe, C
Neoptolemos, J
Affiliation
University of Birmingham, Edgbaston, Birmingham, UKIssue Date
2017-03-01
Metadata
Show full item recordAbstract
Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer.Citation
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. 2017 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(17)30084-0PubMed ID
28259610Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(17)30084-0